Talimogene laherparepvec (T-VEC) demonstrates efficacy in cutaneous BCC, enhancing resectability and altering immune cell composition with low adverse events.
By Tarun Sai LomteReviewed by Lily Ramsey, LLMJan 30 2025 A phase II trial found that T-VEC improved tumor resectability in 50% of patients, leading to early study discontinuation, with strong immune response activation and minimal side effects.
Based on the size and localization of BCC, plastic reconstructive surgery could be required, which may complicate the detection of early local recurrence and thus negatively impact the quality of life and well-being of patients. Talimogene laherparepvec is an OV, a genetically engineered herpes simplex virus 1 , approved for treating injectable, unresectable melanoma lesions in the United States and Europe. T-VEC has a dual mode of action and can alter the tumor microenvironment by activating adaptive and innate immunity.
Twelve patients achieved a pathological non-CR , and six had a pathological CR . The average tumor area reduction was 45.4% until surgery. Moreover, there was a significant increase in CD8+ T cells, CD68+ myeloid cells, and CD20+ B cells infiltrating the interface of tumor islands post-treatment, with a substantial decrease in tumor cell density in patients with a remaining tumor post-treatment.
Skin Virus B Cell Basal Cell Carcinoma Carcinoma CD4 Cell Efficacy Immune Response Surgery Tumor
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Woman Becomes Cancer-Free After UK's First Liver Transplant for Bowel CancerBianca Perea, a 32-year-old trainee lawyer from Manchester, underwent the UK's first liver transplant for advanced bowel cancer and is now cancer-free. Despite being diagnosed with stage four bowel cancer in November 2021, Ms. Perea responded well to treatment including targeted drug therapy, chemotherapy, and surgery. After a liver transplant last summer, Ms. Perea has made a remarkable recovery and has no signs of cancer.
Read more »
Woman Becomes Cancer-Free After UK's First Liver Transplant for Bowel CancerBianca Perea, a 32-year-old from Manchester, received the groundbreaking transplant after battling stage four bowel cancer. Her story highlights the advancements in treatment options for advanced cancer.
Read more »
Liver Cancer Rises as UK's Fastest Growing Cancer DeathResearch reveals liver cancer is increasing at an alarming rate in the UK, driven by obesity, smoking, and alcohol consumption. The death rate has surged from 4.7 to 9.3 per 100,000 people between 1999 and 2019, making it the eighth leading cause of cancer death despite being only the 17th most common in terms of cases. Projections suggest a further 10% increase in the death rate by 2040, potentially placing it as the sixth most deadly cancer.
Read more »
UH Seidman Cancer Center introduces advanced Varian Ethos 2.0 for cancer treatmentRadiation oncologists at UH Seidman Cancer Center have another powerful treatment option for patients diagnosed with many forms of cancer with the addition of Varian Ethos 2.0, capable of a new form of radiotherapy called adaptive radiotherapy.
Read more »
Prostate Cancer Becomes England's Most Common Cancer as Diagnoses SurgeEngland is facing a concerning rise in prostate cancer cases, surpassing breast cancer for the second year in a row. While awareness campaigns are improving early detection, the lack of a national screening program remains a major concern.
Read more »
Prostate Cancer Now Most Common Cancer in EnglandProstate cancer has surpassed breast cancer as the most commonly diagnosed cancer in England, according to a new analysis by Prostate Cancer UK. The charity attributes the increase to greater public awareness leading to more men seeking early diagnoses.
Read more »